Logo image of AKAN

AKANDA CORP (AKAN) Stock Fundamental Analysis

NASDAQ:AKAN - Nasdaq - CA00971M4039 - Common Stock - Currency: USD

1.09  +0.02 (+1.87%)

Fundamental Rating

2

Taking everything into account, AKAN scores 2 out of 10 in our fundamental rating. AKAN was compared to 193 industry peers in the Pharmaceuticals industry. AKAN has a bad profitability rating. Also its financial health evaluation is rather negative. AKAN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AKAN had negative earnings in the past year.
AKAN had a negative operating cash flow in the past year.
In the past 5 years AKAN always reported negative net income.
In the past 5 years AKAN always reported negative operating cash flow.
AKAN Yearly Net Income VS EBIT VS OCF VS FCFAKAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

AKAN has a worse Return On Assets (-51.76%) than 60.62% of its industry peers.
AKAN's Return On Equity of -95.78% is in line compared to the rest of the industry. AKAN outperforms 41.45% of its industry peers.
Industry RankSector Rank
ROA -51.76%
ROE -95.78%
ROIC N/A
ROA(3y)-148.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AKAN Yearly ROA, ROE, ROICAKAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

Looking at the Gross Margin, with a value of 24.91%, AKAN is in line with its industry, outperforming 52.85% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AKAN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 24.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKAN Yearly Profit, Operating, Gross MarginsAKAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

AKAN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKAN has more shares outstanding
Compared to 1 year ago, AKAN has an improved debt to assets ratio.
AKAN Yearly Shares OutstandingAKAN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 200K 400K 600K 800K 1M
AKAN Yearly Total Debt VS Total AssetsAKAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

AKAN has an Altman-Z score of -11.27. This is a bad value and indicates that AKAN is not financially healthy and even has some risk of bankruptcy.
AKAN's Altman-Z score of -11.27 is on the low side compared to the rest of the industry. AKAN is outperformed by 71.50% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that AKAN is not too dependend on debt financing.
AKAN's Debt to Equity ratio of 0.08 is in line compared to the rest of the industry. AKAN outperforms 51.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -11.27
ROIC/WACCN/A
WACC7.69%
AKAN Yearly LT Debt VS Equity VS FCFAKAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

AKAN has a Current Ratio of 1.39. This is a normal value and indicates that AKAN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.39, AKAN is doing worse than 72.02% of the companies in the same industry.
A Quick Ratio of 1.39 indicates that AKAN should not have too much problems paying its short term obligations.
The Quick ratio of AKAN (1.39) is worse than 64.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.39
AKAN Yearly Current Assets VS Current LiabilitesAKAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 98.63% over the past year.
Looking at the last year, AKAN shows a very negative growth in Revenue. The Revenue has decreased by -61.27% in the last year.
Measured over the past years, AKAN shows a very strong growth in Revenue. The Revenue has been growing by 172.39% on average per year.
EPS 1Y (TTM)98.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.31%
Revenue 1Y (TTM)-61.27%
Revenue growth 3Y172.39%
Revenue growth 5YN/A
Sales Q2Q%97.47%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKAN Yearly Revenue VS EstimatesAKAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKAN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKAN Price Earnings VS Forward Price EarningsAKAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKAN Per share dataAKAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

AKAN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKANDA CORP

NASDAQ:AKAN (8/7/2025, 11:01:44 AM)

1.09

+0.02 (+1.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-01 2022-11-01/bmo
Earnings (Next)12-13 2022-12-13/bmo
Inst Owners0.51%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.49M
AnalystsN/A
Price TargetN/A
Short Float %0.75%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.97
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-3.93
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-2.67
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0.37
BVpS1.88
TBVpS1.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.76%
ROE -95.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 24.91%
FCFM N/A
ROA(3y)-148.92%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1486.96%
Cap/Sales 250.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.39
Altman-Z -11.27
F-Score5
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)505.52%
Cap/Depr(5y)N/A
Cap/Sales(3y)97.76%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.31%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-61.27%
Revenue growth 3Y172.39%
Revenue growth 5YN/A
Sales Q2Q%97.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-304.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-165.25%
OCF growth 3YN/A
OCF growth 5YN/A